| 1 |
王洪武，金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
|
| 2 |
王庭丰，陈爱民，陈 欣，等. CTC水平与非小细胞肺癌临床及病理特征的关系[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(5): 676-678.
|
| 3 |
Akhurst T. Staging of non-small-cell Lung Cancer[J]. PET Clin, 2018, 13(1): 1-10.
|
| 4 |
Chassagnon G, Bennani S, Revel MP. Nouvelle classification TNM des cancers du poumon nonà petites cellules [New TNM classification of non-small cell lung cancer][J]. Rev Pneumol Clin, 2017, 73(1): 34-39.
|
| 5 |
Mei D, Luo Y, Wang Y, et al. CT texture analysis of lung adenocarcinoma: can radiomic features be surrogate biomarkers for EGFR mutation statuses[J]. Cancer Imag, 2018, 18(1): 52.
|
| 6 |
Digumarthy SR, Padole AM, Gullo RL, et al. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status[J]? Medicine (Baltimore), 2019, 98(1): 13963.
|
| 7 |
Ye SB, Li R, Shi SS. Epidermal growth factor receptor (EGFR) mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma[J]. Zhonghua Bing Li Xue Za Zhi, 2017, 46(2): 98-101.
|
| 8 |
Cheung AH, Tong JH, Chung LY, et al. EGFR mutation exists in squamous cell lung carcinoma[J]. Pathology, 2020, 52(3): 323-328.
|
| 9 |
Tirier SM, Park J, Preußer F, et al. Pheno-seq-linking visual features and gene expression in 3D cell culture systems[J]. Sci Rep, 2019, 9(1): 12367.
|
| 10 |
Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group[J]. Thorax, 2016, 71(2): 177-184.
|
| 11 |
Taylor J, Manos D, Schmidt H, et al. Canadian association of radiologists：Guide on computed tomography screening for lung cancer[J]. Can Assoc Radiol J, 2017, 68(3): 334-341.
|
| 12 |
Suh CH, Park HS, Kim KW, et al. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15，713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC[J]. Lung Cancer, 2018, 123(1): 60-69.
|
| 13 |
Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
|
| 14 |
Zhang P, Wu X, Tang M, et al. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma[J]. Thorac Cancer, 2019, 10(12): 2218-2224.
|
| 15 |
Jiang M, Zhang Y, Xu J, et al. Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT[J]. Nucl Med Commun, 2019, 40(8): 842-849.
|
| 16 |
Shen TX, Liu L, Li WH, et al. CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma[J]. Cancer Imaging, 2019, 19(1): 34.
|
| 17 |
Tu W, Sun G, Fan L, et al. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology[J]. Lung Cancer, 2019, 132(1): 28-35.
|
| 18 |
Liu X, Wang P, Zhang C, et al. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer[J]. Oncotarget, 2017, 8(30): 50209-50220.
|
| 19 |
Rajaram P, Chandra P, Ticku S, et al. Epidermal growth factor receptor: Role in human cancer[J]. Indian J Dent Res, 2017, 28(6): 687-694.
|
| 20 |
Tsai CJ, Nussinov R. Emerging allosteric mechanism of EGFR activation in physiological and pathological contexts[J]. Biophys J, 2019, 117(1): 5-13.
|
| 21 |
Li X, Yin G, Zhang Y, et al. Predictive power of a radiomic signature based on 18F-FDG PET/CT images for EGFR mutational status in NSCLC[J]. Front Oncol, 2019, 9(1): 1062.
|
| 22 |
Shroff GS, Marom EM, Godoy MCB, et al. CT Signs in the lungs[J]. Semin Ultrasound CT MR, 2019, 40(3): 265-274.
|
| 23 |
Filograna L, Thali MJ. Post-mortem CT imaging of the lungs: pathological versus non-pathological findings[J]. Radiol Med, 2017, 122(12): 902-908.
|
| 24 |
Kramer T, Annema JT. Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer[J]. Lung Cancer, 2021, 161(1): 152-162.
|
| 25 |
Samhouri BF, Koo CW, Yi ES, et al. Is the combination of bilateral pulmonary nodules and mosaic attenuation on chest CT specific for DIPNECH? [J]. Orphanet J Rare Dis, 2021, 16(1): 490.
|
| 26 |
Ojha V, Verma M, Kumar S, et al. Imaging of the spectrum of abnormal systemic arterial supply to the lungs using dual-source CT[J]. Clin Radiol, 2021, 76(3): 2351-2354.
|
| 27 |
Qiao M, Jiang T, Liu X, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: Dusk or Dawn? [J]. J Thorac Oncol, 2021, 16(8): 1267-1288.
|
| 28 |
Talukdar S, Emdad L, Das SK, et al. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells[J]. Adv Cancer Res, 2020, 47(1): 161-188.
|
| 29 |
Park S, Ha S, Lee SH, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor[J]. PLoS One, 2018, 13(1): 0189766.
|
| 30 |
Sacconi B, Anzidei M, Leonardi A, et al. Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates[J]. Clin Radiol, 2017, 72(6): 443-450.
|